Reviews/Omega-3 Fatty Acids/Omega-3 and cardiovascular mortality
CV · OMEGA-CV-02 · v2
Several large randomized trials tested whether taking omega-3 supplements lowers the chance of dying from heart disease. The two trials that directly measured death from cardiovascular causes found no difference between omega-3 and placebo [1], [4]. Trials that measured broader bundles of heart events reached the same no-difference conclusion [2], [3], [7], and a re-run of one of them using a different statistical method also showed nothing clear [5]. The one study suggesting a benefit [9] did not test supplements at all; it measured omega-3 levels already in people's blood and looked at new heart disease rather than death. Because the trials that actually gave people supplements and counted cardiovascular deaths agree on no effect, the panel judged the claim unsupported.
The corpus's only two trials isolating death from cardiovascular causes both show no effect: VITAL [1] reports a hazard ratio of 0.96 (95% CI 0.76 to 1.21) and ORIGINALE [4] reports 0.98 (0.88 to 1.09, P=0.68, 688 vs 700 deaths). Supplementation trials using composite vascular endpoints are likewise null: ASCEND [2] rate ratio 0.97 (0.87 to 1.08), STRENGTH [3] HR 0.99 (0.90 to 1.09) halted for futility, and OMEMI [7] HR 1.08 (0.82 to 1.41). A win-ratio re-analysis of VITAL [5] gives a reciprocal win ratio of 0.90 (0.78 to 1.04), still non-significant. The sole protective signal, Kerminen [9], is observational, with total omega-3 HR 0.95 (0.93 to 0.97) for incident CVD. The contested point: The division is between the null supplementation RCTs and the protective observational association in [9]. That association measures blood omega-3 concentration rather than supplement intake and incident CVD rather than cardiovascular death, so the panel treated it as a different exposure and outcome that cannot offset the trials.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Omega-3 Fatty Acids, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim targets cardiovascular mortality specifically; only [1] and [4] isolate CV death and both are null and precise, so composite-endpoint trials cannot be read as mortality support.
[9] is observational, measures blood omega-3 concentration rather than supplement intake and incident CVD rather than mortality; it cannot carry a supplementation mortality claim and conflicts with the null RCTs.
Where it remains uncertain. The only protective result, [9], is an observational blood-biomarker association (total omega-3 HR 0.95, 0.93 to 0.97) for incident CVD, not a supplementation trial with a mortality endpoint.
Aleatory
Cardiovascular deaths are a minority of counted events even in large trials, so the direct estimates [1], [4] carry sampling noise around a null.
Epistemic
The corpus spans 1 g/day marine n-3 [1], [2], 1.8 g/day [7] and 4 g/day EPA+DHA carboxylic acid [3], but a purified high-dose EPA formulation is named only inside abstracts [9], [10] and is not a corpus trial.
Inferential
Reading [9]'s blood-level association (HR 0.95, 0.93 to 0.97) as supplement efficacy crosses both an exposure gap and an incidence-versus-mortality gap.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest primary-prevention RCT; direct CV-mortality endpoint is null.
“for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21)”
Panel auditInternal validity: high · scope of inference: General US population of men 50+ and women 55+ at usual risk, primary prevention.Key limitations: cardiovascular death is a secondary end point · low supplement dose (1 g/day) · usual-risk population, few events relative to high-risk cohorts
Null vascular composite (incl. vascular death) in diabetics.
“a serious vascular event occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P=0.55)”
Panel auditInternal validity: high · scope of inference: Patients with diabetes but without established atherosclerotic cardiovascular disease.Key limitations: cardiovascular mortality not reported separately · vascular death folded into composite endpoint · diabetes-only population
High-dose EPA+DHA composite including CV death null; trial halted for futility.
“The primary end point occurred in 785 patients (12.0%) treated with omega-3 CA vs 795 (12.2%) treated with corn oil (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84).”
Panel auditInternal validity: high · scope of inference: Statin-treated patients with high cardiovascular risk, hypertriglyceridemia, and low HDL-C.Key limitations: cardiovascular mortality not reported separately · trial halted early · corn oil comparator debate
3 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple large RCTs with direct or composite CV-death endpoints converge on no effect, so confidence that omega-3 supplements reduce cardiovascular mortality is low.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Cardiovascular death as a powered primary endpoint. The claim is specifically about mortality, but only [1] and [4] isolate cardiovascular death and both were powered for composites, leaving the mortality estimate wide. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An RCT of omega-3 supplementation prospectively powered on cardiovascular death as the primary outcome.
Open question: Does omega-3 supplementation reduce death from cardiovascular causes specifically, as opposed to composite vascular events? Why it is still open: Only [1] (HR 0.96, 0.76 to 1.21) and [4] (HR 0.98, 0.88 to 1.09) isolate cardiovascular death, and both intervals remain compatible with a small effect either way.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19